Tally of Risk Factors Can Identify Myeloma Patients at Risk of Deep-vein Blood Clots, Study Suggests
A simple score of risk factors could help alert doctors to a likelihood of dangerous blood clots, called venous thromboembolism, forming as a side…
News
Donor-derived CAR T-cell Therapy ALLO-715 Enters Clinical Testing for Multiple Myeloma
Allogene Therapeutics is launching the first clinical trial testing ALLO-715, its “off-the-shelf” CAR T-cell therapy, for people with multiple myeloma who failed…
CHMP Favors Empliciti Triple Combo to Treat Advanced Multiple Myeloma Patients in EU
The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that Empliciti (elotuzumab)…
MMRF Launches ‘Immune Atlas’ Aiming for Tailored Myeloma Treatments
To ultimately drive immunotherapy discoveries in a complex cancer, the Multiple Myeloma Research Foundation (MMRF) has launched a precision medicine research initiative.
Adding Darzalex to a Velcade-Revlimid Combo Boosts Cancer Disappearance in Newly Diagnosed Multiple Myeloma, Phase 2 Trial Shows
Adding Darzalex (daratumumab) to a treatment combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone increased the proportion of newly diagnosed patients with multiple myeloma showing…
Sleep Apnea Drives Multiple Myeloma in Aggressive Way, Mice Study Finds
Sleep apnea can drive the development of aggressive multiple myeloma in mice resistant to the cancer, a study found, suggesting that the sleep disorder is…
Myeloma UK Launches Research Program Focused on Trial Design
In a continuing effort to support and advance early-phase multiple myeloma studies in the United Kingdom, Myeloma UK is launching a patient-focused research…
Request for Darzalex as Faster and Easier Under-the-skin Infusion for Multiple Myeloma Before FDA
Janssen has asked the U.S. Food and Drug Administration (FDA) to approve a new subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) as a…
Specific DNA Rearrangement Predicts Treatment Resistance, Poor Outcomes in Multiple Myeloma, Study Suggests
A genomic rearrangement involving the immunoglobulin lambda (IgL) gene is predictive of resistance to immunomodulatory agents and poor outcomes among multiple myeloma patients, a new…
FDA Will Review Isatuximab as Potential Therapy for Hard-to-treat Multiple Myeloma
The U.S. Food and Drug Admnistration (FDA) has agreed to review Sanofi’s biologics license application (BLA) for its investigational antibody, isatuximab, as a potential…
